← Back to Clinical Trials
Recruiting NCT05988385

NCT05988385 The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05988385
Status Recruiting
Phase
Sponsor California Pacific Medical Center Research Institute
Condition Obstructive Sleep Apnea
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-04-22
Primary Completion 2027-06-30

Trial Parameters

Condition Obstructive Sleep Apnea
Sponsor California Pacific Medical Center Research Institute
Study Type INTERVENTIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 55 Years
Max Age 85 Years
Start Date 2024-04-22
Completion 2027-06-30
Interventions
Positive airway pressureOral appliance therapyPositional therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomized open-label trial that will screen 400 cognitively normal older adults recruited from well-established sleep clinics at 4 academic medical centers, with newly diagnosed moderate-severe OSA. An expected 200 OSA patients will be then randomized to one of two groups: i) a 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an "effective" AHI4%\< 10/hour and AHI3A\<20/hour (see below); ii) a waitlist control group to receive treatment at the conclusion of the 3-month intervention period. Both groups will continue follow-up for 24 months on stable therapy to determine if sustained improvements in sleep are associated with improvement in cognitive function and AD biomarkers.

Eligibility Criteria

Inclusion Criteria: * Cognitively normal (TiCS ≥29) * Age 55-85 years * Moderate - severe OSA defined as AHI4 ≥20 events/hour or AHI3A\>40/hr using a hypopnea criterion of a 4% oxygen desaturation (AHI4) or 3% oxygen desaturation and/or EEG arousal (AHI3A), or equivalent based on in-home testing - Testing must have been completed in past 12 months or confirmed by repeat test (EHR) * Not currently on therapy for OSA and has not received treatment for OSA for at least 6months * Able and willing to be treated for OSA (Treatment group) * Fluency in English or Spanish Exclusion Criteria: * Documented diagnosis of chronic insomnia, or sleep onset insomnia based on Insomnia Severity Index - a answer of severe or very severe in the screening form * Documented diagnosis of circadian rhythm disorder * Any current use of supplemental oxygen * Other sleep-related breathing disorders (central sleep apnea, etc) based on AASM criteria * Current shift work involving night shift (regular work between 1

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology